Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Novartis

Pharma's expensive gaming of the drug patent system is successfully countered by the Medicines Patent Pool, which increases global access and rewards innovation

Biomedical innovation reached a new era during the COVID-19 pandemic as drug development went into overdrive. But the ways that brand companies license their patented drugs grant them market monopoly, preventing other entities from making generics so they can exclusively profit. This significantly limits the reach of lifesaving drugs, especially…

The Conversation

Gene drug ‘only hope’ for Turkish child, but costs millions

Zolgensma may stop five-year-old Yusuf Polat’s spinal muscular atrophy from progressing, but it costs $2.1m.

Al Jazeera

Queensland researchers find immune-boosting drug could lessen COVID-19 severity if antivirals fade

Unlike antiviral treatments, researchers say the experimental medication would not attack the virus that causes COVID-19, but target the immune system instead.

ABC News

From analysis to the latest developments in health,
read the most diverse news in one place.

Development-supporting new wildlife habitat completes as tragic tale unearthed behind Humber Bank site

Novartis Ings 'opens' bringing pleasure at peaceful use to surviving relatives of German bomb blast

Birmingham Post

Biden Asked OPEC+ To Delay Output Decision, Elon Musk Faces Federal Probe Over Twitter Deal, Netflix Ad-Supported Plan: Top Stories Friday, Oct. 14

Reuters Twitter Says Elon Musk Under Federal Probe Over $44B Twitter Deal, In Court Filing

Benzinga

Pharmaceutical giant Novartis to cut 400 Dublin jobs

Employees were informed of the phased cuts earlier today

Dublin Live

Pollen does more than make you sneeze. It can cause thunderstorm asthma, even if you're not asthmatic

Climate change has caused melting icebergs, flooding, and landslides. It can also bring about an increase in pollen levels, prolong the duration of pollen season, and cause more pollen-related health problems.

The Conversation

Read news from The Economist, FT, and more,
with one subscription

Novartis Whale Trades Spotted

A whale with a lot of money to spend has taken a noticeably bullish stance on Novartis. Looking at options history for Novartis (NYSE:NVS) we detected 21 strange trades.

Benzinga

Top Financial Media Stories Thursday, September 22: Facebook Sued For Bypassing Apple Privacy Rules, Walmart Slows Hiring Plans Ahead Of Holiday Season, China Blames US For Northwestern Polytechnical University Hack And More..

Reuters

Benzinga

'Motorway service station' for migrating birds will put Humber in economic development fast lane

Novartis Ings is taking shape after legacy gift from pharmaceutical giant

Birmingham Post

Benzinga Before The Bell: Twitter Whistleblower Peiter Zatko To Depose Before Senate Panel, GameStop To Boost Employee Compensation To Drive Growth, California Proposes Total Ban On New Gasoline Car Sales By 2035 And Other Top Financial Stories Thursday, August 25

Reuters Stuck By Chip Shortage, Stellantis Halts Production In Sochaux Plant

Benzinga

Recap of Wednesday's Biotech Catalysts - End of The Day Summary

Benzinga

Former Tioxide site relaunched as a major industrial location by ABP as Rolls-Royce shortlisting secured

Sprawling Humber bank location opened up as part of major land release by port operator

Birmingham Post

India’s patent law safeguards under fire

The new recommendation reduces the period within which patent applications can be challenged to six months

The Hindu

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

The Daily Biotech Pulse: Pfizer/BioNTech Ink New COVID-19 Vaccine Supply Pact, Sanofi Hit By FDA Clinical Hold, Angion Biomedica Halts Second Kidney Disease Trial

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Novartis' Tislelizumab Extends Overall Survival In Late-Stage Esophageal Cancer Study

Novartis AG (NYSE: NVS) announced results from the Phase 3 RATIONALE 306 trial of tislelizumab plus chemotherapy in patients with unresectable, locally advanced recurrent or metastatic esophageal squamous cell carcinoma (ESCC).

Benzinga

Novartis Resumes Production, Delivery Of Radioligand Therapy Medicines

Novartis AG (NYSE:NVS) said that in early June, it restarted radioligand therapy (RLT) production at its sites in Ivrea, Italy, and Millburn, New Jersey. It also resumed delivering doses to patients in a phased approach, ahead of the expected six-week timeframe. The company has remediated the issues that led to a temporary, voluntary suspension…

Benzinga

With Zero Revenue, Laekna Plays Chicken-And-Egg Game With Investors

Key Takeaways: Laekna is seeking a Hong Kong IPO to raise funds to accelerate the commercialize two core products licensed from Novartis The company currently is not generating any sale, with most of its products in early stages of development By Tina Yip

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Novartis Announces $250M In R&D Funding For Neglected Tropical Diseases, Malaria

Novartis AG (NYSE:NVS) is pledging $250 million into R&D for new treatments of neglected tropical diseases (NTD) and malaria, with an aim to eliminate these diseases. "Over the past decade, great progress has been made against NTDs, but there is still a lot more work to be done," CEO Vas Narasimhan said. Novartis…

Benzinga

FDA Gives Approval For Novartis' Tafinlar + Mekinist Broadens BRAF/MEK Cancer Combo Use

The FDA granted accelerated approval to Novartis AG's (NYSE:NVS) pairing of Tafinlar and Mekinist for any advanced solid tumors with the BRAF V600E mutation. The patient must have progressed following prior therapy and have no alternative treatment options. The combo is already approved for BRAF mutated non-small cell lung cancer, melanoma, and thyroid cancer.…

Benzinga

Why Precision BioSciences Shares Are Surging Today

Precision BioSciences Inc (NASDAQ:DTIL) has entered into an exclusive worldwide in vivo gene editing research and development collaboration and license agreement with Novartis AG (NYSE:NVS) Precision will develop a custom ARCUS nuclease that will be designed to insert, in vivo, a therapeutic transgene at a "safe harbor" location in the genome as a potential one-time…

The Hindu

Explained | The Indian patent regime and its clash with the U.S. norms

The U.S. Trade Representative highlighted IP challenges in India in its annual Special 301 report released last month

Bangkok Post

Firms rejig to survive in lean times

Businesses adopted cost reduction, increased productivity, and emphasised environmental standards to cope with the pandemic and global challenges stemming from the Russia-Ukraine war, panellists told the Forbes Thailand 2022 Forum on Monday.

Reuters

Novartis drug combo shows promise in childhood brain cancer

An oral drug combination by Swiss pharmaceuticals company Novartis showed promise in treating a subgroup of patients suffering from a common childhood brain cancer in a trial.

Birmingham Post

Work on environmental and economic Novartis 'leaving gift' legacy begins

Wetland habitat to be created to enable future inward investment and economic development at pace

1 … 3 4 5 6

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.